Fresenius Medical Care AG & Co. (NYSE:FMS) has earned a “BB+” credit rating from Morningstar. The research firm’s “BB+” rating indicates that the company is an above-average default risk. They also gave their stock a two star rating.

Separately, analysts at Commerzbank AG downgraded shares of Fresenius Medical Care AG & Co. to a “hold” rating in a research note on Friday, May 29th. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $37.03.

Fresenius Medical Care AG & Co. (NYSE:FMS) opened at 43.28 on Friday. Fresenius Medical Care AG & Co. has a 1-year low of $32.40 and a 1-year high of $44.34. The stock has a 50-day moving average of $42.61 and a 200-day moving average of $41.00. The company has a market cap of $26.30 billion and a price-to-earnings ratio of 25.03.

Fresenius Medical Care AG & Co. (NYSE:FMS) last released its earnings data on Thursday, April 30th. The company reported $0.35 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.40 by $0.05. The company had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.89 billion. The company’s quarterly revenue was up 11.1% on a year-over-year basis. Analysts expect that Fresenius Medical Care AG & Co. will post $1.78 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.

To view more credit ratings from Morningstar, visit www.jdoqocy.comclick-7674909-10651170.

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...